Royalty Pharma plc (RPRX)

Market Cap	26.66B +90.2%
Revenue (ttm)	2.38B +5.1%
Net Income	770.95M -10.2%
EPS	1.78 -6.8%
Shares Out	576.86M
PE Ratio	25.94
Forward PE	9.13
Dividend	$0.94 (2.07%)
Ex-Dividend Date	Feb 20, 2026

Volume	4,176,770
Open	45.44
Previous Close	45.36
Day's Range	45.26 - 46.37
52-Week Range	29.66 - 46.37
Beta	0.42
Analysts	Strong Buy
Price Target	47.75 (+3.33%)
Earnings Date	Feb 11, 2026

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX
• Website: https://www.royaltypharma.com

Financial Performance

In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.

Analyst Summary

According to 4 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price target is $47.75, which is an increase of 3.33% from the latest price.

Price Target

$47.75

(3.33% upside)

Analyst Consensus: Strong Buy